Pfizer, Inc. (PFE) Rating Reiterated by BMO Capital Markets
Pfizer, Inc. (NYSE:PFE)‘s stock had its “buy” rating reiterated by BMO Capital Markets in a research note issued to investors on Thursday. They presently have a $39.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $37.00. BMO Capital Markets’ price target would indicate a potential upside of 7.08% from the company’s current price.
A number of other analysts have also issued reports on PFE. Jefferies Group LLC set a $38.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Monday, October 16th. Berenberg Bank reaffirmed a “hold” rating and set a $36.00 target price (down from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. Barclays PLC set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, Cowen and Company set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $38.26.
Shares of Pfizer (NYSE PFE) traded up 0.50% during midday trading on Thursday, reaching $36.42. The company’s stock had a trading volume of 17,502,245 shares. The firm’s 50 day moving average is $35.56 and its 200 day moving average is $33.83. The firm has a market capitalization of $60.18 billion, a price-to-earnings ratio of 26.58 and a beta of 1.00. Pfizer has a 52 week low of $29.83 and a 52 week high of $36.60.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period last year, the company posted $0.64 earnings per share. The firm’s revenue was down 1.9% compared to the same quarter last year. Equities analysts forecast that Pfizer will post $2.56 EPS for the current fiscal year.
In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the transaction, the insider now directly owns 74,506 shares in the company, valued at $2,436,346.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the transaction, the insider now owns 145,649 shares of the company’s stock, valued at $5,097,715. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the business. Altfest L J & Co. Inc. boosted its stake in Pfizer by 67.0% in the second quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock valued at $3,603,000 after acquiring an additional 43,024 shares during the period. Sphera Funds Management LTD. acquired a new position in Pfizer in the first quarter valued at approximately $13,342,000. Searle & CO. boosted its stake in Pfizer by 92.7% in the first quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock valued at $2,739,000 after acquiring an additional 38,500 shares during the period. Insight 2811 Inc. boosted its stake in Pfizer by 3.7% in the first quarter. Insight 2811 Inc. now owns 9,324 shares of the biopharmaceutical company’s stock valued at $319,000 after acquiring an additional 329 shares during the period. Finally, Washington Trust Bank boosted its stake in Pfizer by 0.7% in the second quarter. Washington Trust Bank now owns 51,052 shares of the biopharmaceutical company’s stock valued at $1,715,000 after acquiring an additional 377 shares during the period. Institutional investors own 68.98% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.